SYED ALI SAFDAR

Allopathic & Osteopathic Physicians|Internal Medicine ZEPHYRHILLS, FL NPI 1760486237

General Payments — all program years on this page

$133.98

  • Category: General Payments
  • Program years: PY2019–2024
  • Record count: 4
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $22.79 across 1 record · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $22.791

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $22.791

By program year

Program yearAmountRecords
2019 $75.571
2023 $35.622
2024 $22.791

Records — PY2024 (1)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1137666568 Takeda Pharmaceuticals U.S.A., Inc. $22.79 01/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.